TRADJENTA: payments to doctors
Payments that named TRADJENTA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2M
- Providers
- 24,516
- Transactions
- 89,704
- Average per transaction
- $22
The per-transaction average — $22 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 24,516 providers the average total is $80, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Boehringer Ingelheim | $1,653,735 | 84.1% |
| Boehringer Ingelheim B.v. | $129,191 | 6.6% |
| Boehringer Ingelheim International GmbH | $93,006 | 4.7% |
| Boehringer Ingelheim (phil.) Inc. | $33,535 | 1.7% |
| Boehringer Ingelheim Singapore Pte. Ltd. | $31,800 | 1.6% |
| Eli Lilly | $9,975 | 0.5% |
| Boehringer Ingelheim Mexico SA De CV | $9,800 | 0.5% |
| Lilly USA, LLC | $3,438 | 0.2% |
| Boehringer Ingelheim India Pvt. Ltd. | $3,000 | 0.2% |